📰 Two Phase News
Two Phase News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Two Phase. Real-time updates on events, politics, business and more.
April 30, 2024
– Total revenues of $881 million in the first quarter – Jakafi® net product revenues of $572 million in Q124, total paid patients increased +5% Y/Y; reiterating full year 2024 guidance of...
April 12, 2024
A supplemental new drug application was submitted for the combination of brexpiprazole and sertraline in the treatment of PTSD in adults.
January 5, 2024
ORION CORPORATION PRESS RELEASE05 JANUARY 2023 at 13:45 EET Orion and MSD Announce Initiation of Two Phase 3 Trials Evaluating ODM-208/MK5684 in Certain...
November 18, 2023
At 16 weeks, patients treated with bimekizumab reported greater improvements in both mean spine pain and morning stiffness when compared with placebo. These improvements continued through week 52.
November 13, 2023
/PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces late-breaking abstract poster presentation of interim results from Phase IIb...
November 11, 2023
Brushless DC Drive Market Analysis and Future Prospects for 2030
November 9, 2023
− FRUZAQLA is the First Targeted Therapy Approved for Metastatic Colorectal Cancer (mCRC) Regardless of Biomarker Status or Prior Types of Therapies in More Than a Decade− FRUZAQLA Plus Best Supportive Care Demonstrated Significant Improvements in Overall Survival, with Corresponding Improvements in Progression Free...
November 9, 2023
Takeda TSE4502NYSETAK today announced that the U.S. Food and Drug Administration FDA has approved FRUZAQLA fruquintinib an oral targeted therapy for adults with metastatic colorectal cancer mCRC who have been previously treated with fluoropyrimidine oxaliplatin and irinotecanbased chemotherapy an antiVEGF therapy and if RAS wildtype and medically appropriate an antiEGFR therapy.
November 8, 2023
OSAKA, Japan & CAMBRIDGE, Mass., November 08, 2023--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved FRUZAQLA™ (fruquintinib), an oral targeted therapy for adults with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy. FRUZAQLA is the first and onl...
October 31, 2023
– Total revenues of $919 million in the third quarter – Jakafi® net product revenues of $636 million in Q323, $1.9 billion YTD 2023, driven by growth in total patients across all...